Alnylam Pharmaceuticals, Inc Aktie News

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Par...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights. “2024 is off to a strong start, with exceptional commercial performance where we delivered $365 million in global net product revenues, represe...

The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient global commercialization of Alnylam's innovative RNAi technologies ZUG, Switzerland, April 30, 2024 /PRNewswire/ -- Medison ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2024 results as well as expectations f...

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnyl...

NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnyl...

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnyl...

NEW YORK, NY / ACCESSWIRE / April 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnyl...